A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of the study is to evaluate the effects of food intake on the plasma concentration profile of YNO-5920/YM529 in post menopausal women.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Ono Pharma USA Inc
• Treatments: Diphosphonates

Criteria

Inclusion Criteria:

• Post menopausal women (at least 2 years after menopause)

• Body weight: more than 40.0 Kg and less than 70.0 Kg

• BMI: more than 17.6 and less than 30.0

Exclusion Criteria:

• Receives investigational drug within 120 day before the study

• Blood donation before the study

• With abnormal laboratory values